Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Journal of Medicinal Chemistry
|
June 15, 2017
A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose
Timothy B Durham, Jothirajah Marimuthu, James L Toth, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
May 13, 2025
LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy Adults
Tsuyoshi Fukuda, Brian R Thompson, Bram Brouwers, et al.
Journal of Medicinal Chemistry
|
October 5, 2022
Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors
Rongjun He, Jifeng Wang, Zhi-Hong Yu, et al.
Journal of Medicinal Chemistry
|
May 20, 2016
Use of Osmotic Pumps to Establish the Pharmacokinetic-Pharmacodynamic Relationship and Define Desirable Human Performance Characteristics for Aggrecanase Inhibitors
Michael R Wiley, Timothy B Durham, Lisa A Adams, et al.
Journal of Medicinal Chemistry
|
November 22, 2014
Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis
Timothy B Durham, Valentine J Klimkowski, Christopher J Rito, et al.
Journal of Medicinal Chemistry
|
November 1, 2017
Optimization of Hydroxyethylamine Transition State Isosteres as Aspartic Protease Inhibitors by Exploiting Conformational Preferences
Ana B Bueno, Javier Agejas, Howard Broughton, et al.
Ebiomedicine
|
January 2, 2018
CMPF, a Metabolite Formed Upon Prescription Omega-3-Acid Ethyl Ester Supplementation, Prevents and Reverses Steatosis
Kacey J Prentice, Stacy G Wendell, Ying Liu, et al.
Journal of Medicinal Chemistry
|
November 22, 2023
Identification of LY3522348: A Highly Selective and Orally Efficacious Ketohexokinase Inhibitor
Timothy B Durham, Junliang Hao, Patrick Spinazze, et al.
The Journal of Biological Chemistry
|
June 19, 2015
Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo
Timothy B Durham, James L Toth, Valentine J Klimkowski, et al.
Journal of Medicinal Chemistry
|
October 27, 2017
Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Cancer Xenograft Model
Kevin R Fales, F George Njoroge, Harold B Brooks, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Journal of Medicinal Chemistry
|
June 15, 2017
A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose
Timothy B Durham, Jothirajah Marimuthu, James L Toth, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
May 13, 2025
LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy Adults
Tsuyoshi Fukuda, Brian R Thompson, Bram Brouwers, et al.
Journal of Medicinal Chemistry
|
October 5, 2022
Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors
Rongjun He, Jifeng Wang, Zhi-Hong Yu, et al.
Journal of Medicinal Chemistry
|
May 20, 2016
Use of Osmotic Pumps to Establish the Pharmacokinetic-Pharmacodynamic Relationship and Define Desirable Human Performance Characteristics for Aggrecanase Inhibitors
Michael R Wiley, Timothy B Durham, Lisa A Adams, et al.
Journal of Medicinal Chemistry
|
November 22, 2014
Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis
Timothy B Durham, Valentine J Klimkowski, Christopher J Rito, et al.
Journal of Medicinal Chemistry
|
November 1, 2017
Optimization of Hydroxyethylamine Transition State Isosteres as Aspartic Protease Inhibitors by Exploiting Conformational Preferences
Ana B Bueno, Javier Agejas, Howard Broughton, et al.
Ebiomedicine
|
January 2, 2018
CMPF, a Metabolite Formed Upon Prescription Omega-3-Acid Ethyl Ester Supplementation, Prevents and Reverses Steatosis
Kacey J Prentice, Stacy G Wendell, Ying Liu, et al.
Journal of Medicinal Chemistry
|
November 22, 2023
Identification of LY3522348: A Highly Selective and Orally Efficacious Ketohexokinase Inhibitor
Timothy B Durham, Junliang Hao, Patrick Spinazze, et al.
The Journal of Biological Chemistry
|
June 19, 2015
Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo
Timothy B Durham, James L Toth, Valentine J Klimkowski, et al.
Journal of Medicinal Chemistry
|
October 27, 2017
Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Cancer Xenograft Model
Kevin R Fales, F George Njoroge, Harold B Brooks, et al.
Page
of 3